Figure 3From: A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial Kaplan–Meier curve of progression-free survival (PFS) for the primary efficacy population (n = 187). Back to article page